Positive Phase 2 results for TOPICA’s luliconazole

Positive Phase 2 results for TOPICA’s luliconazole

TOPICA Pharmaceuticals had positive results from its Phase 2 clinical study evaluating luliconazole, a topical antifungal agent, in patients with tinea pedis (athlete’s foot). The study assessed the effectiveness of luliconazole cream applied once daily for 14 days compared with once daily for 28 days.